{"id":"https://openalex.org/W4417314671","doi":"https://doi.org/10.1158/1078-0432.30883081","title":"Suppl Table 1 and Figure 1 from LRP1b Loss Predicts Sensitivity to Immunotherapy in Patients with NSCLC: An Analysis of the Phase III CheckMate-026 Randomized Trial","display_name":"Suppl Table 1 and Figure 1 from LRP1b Loss Predicts Sensitivity to Immunotherapy in Patients with NSCLC: An Analysis of the Phase III CheckMate-026 Randomized Trial","publication_year":2025,"publication_date":"2025-12-15","ids":{"openalex":"https://openalex.org/W4417314671","doi":"https://doi.org/10.1158/1078-0432.30883081"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.30883081","doi":"https://doi.org/10.1158/1078-0432.30883081","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.30883081","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"other","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1158/1078-0432.30883081","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5038489185","display_name":"Andrew J. Armstrong","orcid":"https://orcid.org/0000-0001-7012-1754","observed_orcids":["https://orcid.org/0000-0001-7012-1754"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Andrew J. Armstrong","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-7012-1754","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081394579","display_name":"Hilary Dietz","orcid":"https://orcid.org/0000-0001-9586-9902","observed_orcids":["https://orcid.org/0000-0001-9586-9902"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hilary Dietz","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-9586-9902","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056258535","display_name":"David Balli","orcid":"https://orcid.org/0009-0000-9877-9347","observed_orcids":["https://orcid.org/0009-0000-9877-9347"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"David Balli","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0000-9877-9347","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109402311","display_name":"William J. Geese","orcid":"https://orcid.org/0009-0006-9371-5487","observed_orcids":["https://orcid.org/0009-0006-9371-5487"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"William J. Geese","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0006-9371-5487","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031123462","display_name":"Chunzhe Duan","orcid":"https://orcid.org/0009-0008-5368-3198","observed_orcids":["https://orcid.org/0009-0008-5368-3198"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Chunzhe Duan","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0008-5368-3198","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063666525","display_name":"Yu-Han Hung","orcid":"https://orcid.org/0000-0002-3278-3201","observed_orcids":["https://orcid.org/0000-0002-3278-3201"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yu-Han Hung","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-3278-3201","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020053393","display_name":"Virginia Ip","orcid":"https://orcid.org/0009-0001-1448-6633","observed_orcids":["https://orcid.org/0009-0001-1448-6633"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Virginia Ip","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0001-1448-6633","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044148216","display_name":"Gerald Li","orcid":"https://orcid.org/0000-0002-5617-6262","observed_orcids":["https://orcid.org/0000-0002-5617-6262"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Gerald Li","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-5617-6262","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025819053","display_name":"Ryon P. Graf","orcid":"https://orcid.org/0000-0002-8065-4148","observed_orcids":["https://orcid.org/0000-0002-8065-4148"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ryon P. Graf","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-8065-4148","affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5079438136","display_name":"Neal Ready","orcid":"https://orcid.org/0000-0003-4414-9432","observed_orcids":["https://orcid.org/0000-0003-4414-9432"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Neal Ready","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-4414-9432","affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9897000193595886,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9897000193595886,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.008899999782443047,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12334","display_name":"Lung Cancer Research Studies","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/lrp1b","display_name":"LRP1B","score":0.9150000214576721},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.9459999799728394},{"id":"https://openalex.org/keywords/immunotherapy-sensitivity","display_name":"immunotherapy sensitivity","score":0.8500000238418579},{"id":"https://openalex.org/keywords/predictive-biomarkers","display_name":"predictive biomarkers","score":0.8240000009536743},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.6330000162124634},{"id":"https://openalex.org/keywords/pd-1-inhibitors","display_name":"PD-1 inhibitors","score":0.5910000205039978},{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":0.7049999833106995},{"id":"https://openalex.org/keywords/atezolizumab","display_name":"atezolizumab","score":0.8640000224113464}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7361000180244446},{"id":"https://openalex.org/C21200559","wikidata":"https://www.wikidata.org/wiki/Q7451068","display_name":"Sensitivity (control systems)","level":2,"score":0.6295999884605408},{"id":"https://openalex.org/C45235069","wikidata":"https://www.wikidata.org/wiki/Q278425","display_name":"Table (database)","level":2,"score":0.6269000172615051},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.6017000079154968},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.4431000053882599},{"id":"https://openalex.org/C44280652","wikidata":"https://www.wikidata.org/wiki/Q104837","display_name":"Phase (matter)","level":2,"score":0.3686999976634979},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.3504999876022339},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.32760000228881836},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.3077999949455261},{"id":"https://openalex.org/C3018822202","wikidata":"https://www.wikidata.org/wiki/Q1324077","display_name":"Patient data","level":2,"score":0.28850001096725464}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1078-0432.30883081","doi":"https://doi.org/10.1158/1078-0432.30883081","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.30883081","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.30883081","doi":"https://doi.org/10.1158/1078-0432.30883081","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.30883081","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9476000070571899,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4417314672","https://openalex.org/W4417315101","https://openalex.org/W4414994041","https://openalex.org/W6939700602","https://openalex.org/W6939885043","https://openalex.org/W6958810135","https://openalex.org/W6977266189","https://openalex.org/W6931282372","https://openalex.org/W7117307618","https://openalex.org/W6921033671"],"abstract_inverted_index":{"Supplementary":[0,4],"Table":[1],"1":[2,6],"and":[3],"Figure":[5]},"counts_by_year":[],"updated_date":"2026-10-28T10:33:24.094632","created_date":"2025-12-15T00:00:00"}